Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/31/2002WO2002068390A8 Diamides which inhibit tryptase and factor xa activity
10/31/2002WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002WO2002067654A3 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
10/31/2002WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002WO2002066021A3 Protein kinase d inhibitors and protein kinase 2 inhibitors as agents for inhibiting tumour cells and for stimulating angiogenesis
10/31/2002WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002WO2002054066A3 Non-apoptotic forms of cell death and methods of modulation
10/31/2002WO2002053185A3 Anti-inflammatory use of polycationic compounds
10/31/2002WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002WO2002041896A3 Use of thienopyrimidines
10/31/2002WO2002040045A3 Microspheres of pancreatic enzymes with high stability
10/31/2002WO2002033080A3 Regulation of human netrin binding membrane receptor unc5h-1
10/31/2002WO2002028874A3 Tumor proliferation inhibitors
10/31/2002WO2002024912A3 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
10/31/2002WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002WO2002014499A3 Claudin polypeptides
10/31/2002WO2002012502A3 Anti-tnf antibodies, compositions, methods and uses
10/31/2002WO2002004002A3 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
10/31/2002WO2002000262A3 Modulation of chromosome function by chromatin remodeling agents
10/31/2002WO2001098343A3 Conserved diaphanous-related formin autoregulatory domain (dad)
10/31/2002WO2001093897A3 Angiostatin and endostatin binding proteins and methods of use
10/31/2002WO2001087348A3 Multifunctional nanodevice platform
10/31/2002WO2001070675A3 Inhibitors of histone deacetylase
10/31/2002WO2001061356A9 Her-2 binding antagonists
10/31/2002WO2001058855A9 Use of androgen receptor suppressors
10/31/2002WO2001058479A9 Immunotherapy using interleukin 13 receptor subunit alpha 2
10/31/2002WO2001056601A9 Low dose haptenized tumor cell and tumor cell extract immunotherapy
10/31/2002WO2001056563A9 Adamantyl derivatives as anti-cancer agents
10/31/2002WO2001055432A3 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications
10/31/2002WO2001053342A9 Chimeric prostate-homing peptides with pro-apoptotic activity
10/31/2002WO2001052746A9 Versatile hydrophilic dyes
10/31/2002WO2001051633A9 Compositions and methods for the therapy and diagnosis of prostate cancer
10/31/2002WO2001000198A3 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity
10/31/2002WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002US20020161245 From salicylaldehyde derivatives and alkyl cyanoacetates and using a molecular sieve; chromene derivatives that bind to Bcl-2 protein and induce apoptosis in tumor cells
10/31/2002US20020161226 Quinazolines for treating brain tumor
10/31/2002US20020161220 Tetraphosphonate bicyclic trisanhydrides
10/31/2002US20020161212 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
10/31/2002US20020161206 For inhibiting tumor cell growth
10/31/2002US20020161201 For use in cancer diagnosis and therapy
10/31/2002US20020161178 Novel DKR polypeptides
10/31/2002US20020161053 Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents
10/31/2002US20020161045 Novel acetyloxymethyl esters and methods for using the same
10/31/2002US20020161036 Chalcone coumarins
10/31/2002US20020161035 Medicaments for chemotherapeutic treatment of disease
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161022 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161007 Non-steroidal modulators of estrogen receptors
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161004 Antiinflammation agents
10/31/2002US20020161000 Treating diseases resulting from tissue breakdown such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, atherosclerosis, and osteoporosis
10/31/2002US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002US20020160983 Substituted benzopyranones as telomerase inhibitors
10/31/2002US20020160969 Nucleosides and oligonucleotides containing boron clusters
10/31/2002US20020160963 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
10/31/2002US20020160959 Therapeutic compounds for ovarian cancer
10/31/2002US20020160957 Treating tumors
10/31/2002US20020160948 Such as preventing or treating primary cancer cell growth
10/31/2002US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160502 For use in immunotherapy
10/31/2002US20020160493 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
10/31/2002US20020160484 Central nervous system disorders therapy; genetic engineering
10/31/2002US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002US20020160477 CAF1-related protein
10/31/2002US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002US20020160379 Gapped 2' modified oligonucleotides
10/31/2002US20020160362 Measurement variations of allele polypeptides gene; diagnosis of arthritis, cancer
10/31/2002US20020160039 Infusing lipid/alcohol solution directly into aqueous polymer solution; resulting liposome which may be incorporated with a pharmaceutical substance consists of multilamellar vesicles of average size of 1-8 microns
10/31/2002US20020160014 Cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells
10/31/2002US20020160011 Adjuvant compositions for vaccines
10/31/2002US20020160006 Methods of treating lymphoma and leukemia
10/31/2002US20020160003 Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002DE10120627A1 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren Use of Phyllanthus for the treatment or prophylaxis of infections caused by hepatitis B viruses
10/31/2002DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002CA2445250A1 Three-step conversion of protected taxane ester to paclitaxel
10/31/2002CA2445202A1 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002CA2445168A1 Human timp-1 antibodies
10/31/2002CA2445071A1 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002CA2445042A1 Two-step conversion of protected taxane ester to paclitaxel
10/31/2002CA2444691A1 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444599A1 Melanocortin receptor ligands
10/31/2002CA2444471A1 Synthesis of pancratistatin prodrugs
10/31/2002CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002CA2444219A1 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002CA2443946A1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
1 ... 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 ... 2211